Pirtobrutinib Showed Positive Efficacy and Safety vs Ibrutinib in BTKi-naïve CLL/SLL Patients Both for Treatment-naïve Patients and Patients with R/R Disease

In this MEDtalk, Wojciech Jurczak, MD, PhD, from the Maria Skłodowska-Curie National Institute of Oncology in Krakow, Poland, presents data from the first randomized, head-to-head comparison of pirtobrutinib—a highly selective, noncovalent Bruton tyrosine kinase inhibitor (BTKi)—versus ibrutinib in BTKi-naïve patients with CLL/SLL, including both treatment-naïve and relapsed/refractory populations.